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BACKGROUND: Goals of management in patients with heart failure and reduced 
ejection fraction include reducing death and hospitalizations, and improving health 
status (symptoms, physical function, and quality of life). In the DAPA-HF trial 
(Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose 
cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and 
improved symptoms in patients with heart failure and reduced ejection fraction. In 
this analysis, we examine the effects of dapagliflozin on a broad range of health 
status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ).
METHODS: KCCQ was evaluated at randomization, 4 and 8 months. Patients 
were divided by baseline KCCQ total symptom score (TSS); Cox proportional 
hazards models examined the effects of dapagliflozin on clinical events across these 
subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical 
summary score, and overall summary score. Responder analyses were performed to 
compare proportions of dapagliflozin versus placebo-treated patients with clinically 
meaningful changes in KCCQ at 8 months.
RESULTS: A total of 4443 patients had available KCCQ at baseline (median KCCQ-
TSS, 77.1 [interquartile range, 58.3–91.7]). The effects of dapagliflozin vs placebo on 
reducing cardiovascular death or worsening heart failure were consistent across the 
range of KCCQ-TSS (lowest to highest tertile: hazard ratio, 0.70 [95% CI, 0.57–0.86]; 
hazard ratio, 0.77 [95% CI, 0.61–0.98]; hazard ratio, 0.62 [95% CI, 0.46–0.83]; P 
for heterogeneity=0.52). Patients treated with dapagliflozin had greater improvement 
in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months 
(2.8, 2.5 and 2.3 points higher versus placebo; P<0.0001 for all). Fewer patients 
treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio, 0.84 [95% 
CI, 0.78–0.90]; P<0.0001); and more patients had at least small, moderate, and 
large improvements (odds ratio, 1.15 [95% CI, 1.08–1.23]; odds ratio, 1.15 [95% CI, 
1.08–1.22]; odds ratio, 1.14 [95% CI, 1.07–1.22]; number needed to treat=14, 15, 
and 18, respectively; P<0.0001 for all; results consistent for KCCQ clinical summary 
score and overall summary score).
CONCLUSIONS: Dapagliflozin reduced cardiovascular death and worsening heart 
failure across the range of baseline KCCQ, and improved symptoms, physical 
function, and quality of life in patients with heart failure and reduced ejection 
fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing 
at least small, moderate, and large improvements in health status; these effects were 
clinically important.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT03036124.
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Patients with heart failure (HF) and reduced ejection fraction (HFrEF) are at high risk of disease progres-sion, resulting in clinical deterioration, repeat hos-
pitalizations, and death.1 Importantly, they also expe-
rience a high burden of debilitating symptoms, which 
impact their daily function and quality of life. Of note, 
some treatments for HFrEF (such as β-blockers) that 
have a favorable effect on death and hospitalizations 
do not improve health status,2 highlighting the high 
unmet need for additional efficacious therapies that 
not only improve clinical events but also reduce symp-
tom burden and physical limitations, and improve the 
quality of life. In fact, improving patients’ health status 
(which includes symptom burden, physical limitations, 
and quality of life) is a key goal of HF management, in-
creasingly recognized by the practice guidelines,3,4 and 
acknowledged by regulators as an important outcome.5
In the placebo-controlled DAPA-HF trial (Dapa-
gliflozin and Prevention of Adverse-Outcomes in Heart 
Failure) trial, the sodium–glucose cotransporter-2 in-
hibitor, dapagliflozin, added to other guideline-recom-
mended therapies, reduced the risk of mortality and HF 
hospitalization, and improved symptoms in 4744 pa-
tients with HFrEF.6 In the current analysis, we sought 
to address the following two objectives: (1) to evalu-
ate whether the effects of dapagliflozin on clinical out-
comes in the DAPA-HF trial varied according to the de-
gree of symptomatic impairment at baseline; and (2) 
to examine the effects of dapagliflozin on the broad 
range of health status outcomes, as measured by the 
various domains of the Kansas City Cardiomyopathy 
Questionnaire (KCCQ)—a validated, self-administered 
instrument that quantifies HF-related symptoms, func-
tion, and quality of life.
METHODS
Data underlying the findings described in this manuscript 
may be obtained in accordance with AstraZeneca’s data 
sharing policy.7 DAPA-HF was a randomized, double-blind, 
controlled trial in patients with HFrEF, which evaluated the 
efficacy and safety of dapagliflozin 10 mg once daily, com-
pared with matching placebo, added to standard care. The 
design, baseline characteristics, and primary results of the trial 
have been published.8 The Ethics Committee of each of the 
410 participating institutions (in 20 countries) approved the 
protocol, and all patients gave written informed consent. The 
corresponding author had full access to all of the trial data 
and takes responsibility for its integrity and the data analysis.
Study Patients
Men and women aged ≥18 years with HF were eligible if they 
were in New York Heart Association (NYHA) functional class 
≥II, had a left ventricular ejection fraction ≤40%, and were 
optimally treated with pharmacological and device therapy 
for HF. Participants were also required to have a NT-proBNP 
(N-terminal pro-B-type natriuretic peptide) concentration ≥600 
pg/mL (≥400 pg/mL if hospitalized for HF within the previous 
12 months). Patients with atrial fibrillation or atrial flutter were 
required to have a NT-proBNP level ≥900 pg/mL, irrespective of 
history of HF hospitalization. Key exclusion criteria included the 
following: symptoms of hypotension or systolic blood pressure 
<95 mm Hg, estimated glomerular filtration rate <30 mL/min 
per 1.73 m2 (or rapidly declining renal function), type 1 dia-
betes mellitus, and other conditions likely to prevent patient 
participation in the trial or greatly limit life expectancy. A full 
list of exclusion criteria is provided in the design manuscript.9
Study Procedures
After the provision of informed consent, visit 1 started a 14-day 
screening period during which the trial inclusion and exclu-
sion criteria were checked, and baseline information was col-
lected. Visit 2 was the randomization visit, and randomization 
was stratified based on diagnosis of type 2 diabetes mellitus 
(defined as an established diagnosis or a glycated hemoglobin 
level of ≥6.5% [≥48 mmol per mole]). After randomization, 
follow-up visits took place at 14 and 60 days, and then at 
120, 240, and 360 days and every 4 months thereafter. The 
visit early after randomization (14 days) was included to check 
renal function and blood pressure (as well as for symptoms of 
hypotension); this visit also allowed for adjustment of back-
ground diuretic or other nonessential therapies. Dose reduc-
tion (to 5 mg daily of dapagliflozin or placebo) or temporary 
discontinuation of study drug was to be considered in case of 
an acute unexpected decline in estimated glomerular filtra-
tion rate, volume depletion, or hypotension (or to avoid these 
conditions); however, dose up-titration (or reinitiation) was 
encouraged thereafter in all cases, where possible.
Clinical Perspective
What Is New?
• Dapagliflozin improved cardiovascular death or 
worsening heart failure in patients with heart fail-
ure and reduced ejection fraction regardless of the 
level of symptomatic impairment at baseline.
• Dapagliflozin improved symptom burden, physical 
function, and quality of life in patients with heart 
failure and reduced ejection fraction; these effects 
were sustained and amplified over time.
• Dapagliflozin significantly increased the proportion 
of patients experiencing at least small, moderate, 
and large improvements in health status; these 
effects were clinically important.
What Are the Clinical Implications?
• The beneficial effects of dapagliflozin on heart fail-
ure outcomes are independent of the health status 
impairment at baseline.
• Our findings indicate that dapagliflozin signifi-
cantly improves heart failure–related health status 
(symptoms, physical function, and quality of life), 
as measured by the Kansas City Cardiomyopathy 
Questionnaire, with the benefits emerging early 
and being sustained long-term.
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Clinical Outcomes
The primary outcome in the DAPA-HF trial was the composite 
of an episode of worsening HF (HF hospitalization or urgent 
HF visit) or cardiovascular death, whichever occurred first. 
Additional clinical outcomes assessed in the current study 
were the occurrence of HF hospitalization or cardiovascular 
death; worsening HF events (HF hospitalizations or urgent 
HF visits), hospitalization for HF, cardiovascular death, and 
all-cause death.
Kansas City Cardiomyopathy 
Questionnaire
The KCCQ was completed electronically by patients, with-
out assistance by site study staff (as validated), and evaluated 
at randomization, 4 months, and 8 months. The KCCQ is 
a 23-item, self-administered disease-specific instrument that 
quantifies symptoms (frequency, severity, and recent change), 
physical function, quality of life, and social function over the 
previous 2 weeks. In the KCCQ, the total symptom score 
(TSS) quantifies the symptom frequency and severity, KCCQ 
clinical summary score (CSS) includes the physical function 
and symptoms domains, and KCCQ overall summary score 
(OSS) is derived from total symptom score, physical func-
tion, quality of life, and social function. For each domain, 
the validity, reproducibility, responsiveness, and interpretabil-
ity have been independently established. Scores are trans-
formed to a range of 0 to 100, in which higher scores reflect 
better health status.10
Statistical Analysis
In the present post hoc analysis, patients were divided into 
3 subgroups, based on the tertiles of baseline KCCQ-TSS 
(which was the KCCQ domain prespecified as the secondary 
end point): (i) ≤65.6, (ii) 65.7 to 87.5, and (iii) >87.5 points. 
Baseline characteristics were summarized as means and SDs, 
medians, and interquartile ranges, or percentages. A Cuzick 
extension of the Wilcoxon test for trend was used to compare 
trends across categories of KCCQ.11 The rates of cardiovascu-
lar death and worsening HF across the tertiles of KCCQ-TSS 
(regardless of treatment allocation) were calculated and com-
pared using Kaplan-Meier estimates.
To compare the effects of dapagliflozin versus placebo on 
clinical outcomes across the KCCQ-TSS tertiles, we evaluated 
time-to-event data with the use of Kaplan-Meier estimates 
and used Cox proportional-hazards models, stratified accord-
ing to diabetes mellitus status, with a history of HF hospi-
talization and treatment-group assignment as fixed-effect 
factors to calculate hazard ratios (HR), 95% CIs, and two-
sided P values.
We analyzed the differences between treatment groups in 
mean KCCQ-TSS, CSS, and OSS at 4 months and 8 months 
in surviving patients, using a mixed model for repeated mea-
surements and estimated the least-squares mean differences 
between treatment groups adjusted for baseline KCCQ values. 
We conducted responder analyses examining proportions of 
patients with a deterioration, and clinically important improve-
ments in KCCQ at 8 months. We used established, clinically 
meaningful thresholds for KCCQ (≥5 point [at least small], 
≥10 point [moderate], and ≥15 point [large] change) for all 
responder analyses across the KCCQ domains.12 The propor-
tion of responders was compared between those treated 
with dapagliflozin vs placebo using multiple imputation to 
account for missing KCCQ values (see below). Odds ratios 
(ORs) to estimate differences between treatment groups, and 
their corresponding 95% CI and 2-sided P values were esti-
mated from logistic regression models (which included treat-
ment group, stratification variable (type 2 diabetes mellitus at 
randomization), and baseline KCCQ values); the models used 
imputed data accounting for missing KCCQ values, and esti-
mates were combined using Rubin’s rules. Missing data were 
imputed using a missing at random assumption and a predic-
tive mean matching multiple imputation model, and a method 
of Fully Conditional Specification as implemented in the SAS 
Procedure MI (Fully Conditional Specification [FCS] statement). 
The imputation model included the treatment group, type 2 
diabetes mellitus randomization stratum, KCCQ scores at 
baseline, 4 months, and 8 months, and a categorical variable 
representing the number of investigator reported HF events (0, 
1, ≥2 events) in the interval from randomization to 4 months, 
and in the interval from 4 to 8 months. Patients who died 
were counted as not improved in the analysis of improvement, 
or deteriorated in the analysis of deterioration. Patients with 
a baseline KCCQ score too high for them to experience an 
improvement according to a certain threshold (eg, baseline 
score ≥95 points for the 5-point threshold) were defined as 
improved if their score remained high (ie, ≥95 points) at 8 
months. Similarly, patients with at KCCQ score at baseline too 
low for them to experience a deterioration were defined as 
deteriorated if their score remained low at 8 months. Number 
needed to treat (NNT) with their corresponding 95% CI were 
calculated using the method described by Bender.13 All analy-
ses were conducted using STATA version 15.1 (College Station, 
TX) and SAS version 9.4 (SAS Institute, Cary, NC). A P value of 
0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Overall, 4443 patients (93.7% of the overall trial popula-
tion) had available KCCQ data at baseline. Baseline char-
acteristics of patients with recorded vs missing KCCQ-TSS 
at randomization are presented in Table I in the online-only 
Data Supplement. There were a few modest differences 
between those with and without available KCCQ-TSS at 
baseline, although most clinical characteristics were simi-
lar. Notably, patients randomized to dapagliflozin versus 
placebo were equally distributed among those with re-
corded and missing KCCQ-TSS at baseline. Importantly, 
there was also no difference in clinical outcomes between 
patients that had KCCQ-TSS recorded versus missing at 
randomization (Table II in the online-only Data Supple-
ment). Of these, 4141 patients (89.7% of surviving pa-
tients) had KCCQ evaluated at 4 months (130 missing 
KCCQ data due to death, 473 missing for reasons other 
than death); and 3955 (88.3% of surviving patients) had 
KCCQ evaluated at 8 months (257 missing KCCQ data 
due to death, 532 missing KCCQ data for reasons other 
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Table. Baseline Characteristics of the KCCQ Study Population
KCCQ-TSS at Baseline
P Value for 
TrendTertile 1 N=1487 Tertile 2 N=1564 Tertile 3 N=1392 Total N=4443
Age, y 65.8 (11.0) 66.4 (10.5) 66.8 (10.5) 66.3 (10.7) 0.007
Sex <0.001
  Female 414 (27.8%) 344 (22.0%) 233 (16.7%) 991 (22.3%)  
  Male 1073 (72.2%) 1220 (78.0%) 1159 (83.3%) 3452 (77.7%)  
Race <0.001
  Asian 183 (12.3%) 349 (22.3%) 455 (32.7%) 987 (22.2%)  
  Black 100 (6.7%) 59 (3.8%) 52 (3.7%) 211 (4.7%)  
  White 1175 (79.0%) 1141 (73.0%) 864 (62.1%) 3180 (71.6%)  
  Other 29 (2.0%) 15 (1.0%) 21 (1.5%) 65 (1.5%)  
Geographic region <0.001
  Asia/Pacific 180 (12.1%) 342 (21.9%) 447 (32.1%) 969 (21.8%)  
  Europe 803 (54.0%) 750 (48.0%) 511 (36.7%) 2064 (46.5%)  
  North America 226 (15.2%) 222 (14.2%) 196 (14.1%) 644 (14.5%)  
  South America 278 (18.7%) 250 (16.0%) 238 (17.1%) 766 (17.2%)  
Systolic BP, mm Hg 121.5 (16.1) 121.4 (16.3) 122.6 (16.4) 121.8 (16.3) 0.102
Diastolic BP, mm Hg 73.9 (10.1) 73.3 (10.4) 73.5 (10.9) 73.5 (10.5) 0.151
Pulse, bpm 72.7 (12.1) 71.0 (11.4) 70.4 (11.4) 71.4 (11.7) <0.001
Body mass index, kg/m2 29.8 (6.6) 28.0 (5.6) 27.0 (5.2) 28.3 (5.9) <0.001
Creatinine, mg/dL 1.2 (0.4) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.007
eGFR, mL/min per 1.73 m2 64.2 (19.1) 65.9 (19.2) 66.9 (19.2) 65.7 (19.2) <0.001
NT-proBNP, pg/mL 1716.2  
(964.0–3274.7)
1389.0  
(827.8–2517.9)
1291.6  
(798.9–2172.4)
1432.0  
(855.1–2635.7)
<0.001
Main cause of HF 0.034
  Ischemic 865 (58.2%) 886 (56.6%) 755 (54.2%) 2506 (56.4%)  
  Nonischemic 497 (33.4%) 565 (36.1%) 518 (37.2%) 1580 (35.6%)  
  Unknown 125 (8.4%) 113 (7.2%) 119 (8.5%) 357 (8.0%)  
LVEF (%) 31.2 (6.8) 31.0 (6.8) 31.0 (6.7) 31.1 (6.8) 0.184
NYHA class <0.001
  II 745 (50.1%) 1108 (70.8%) 1139 (81.8%) 2992 (67.3%)  
  III 724 (48.7%) 443 (28.3%) 242 (17.4%) 1409 (31.7%)  
  IV 18 (1.2%) 13 (0.8%) 11 (0.8%) 42 (0.9%)  
KCCQ-TSS 51.0 (40.6–58.3) 79.2 (72.4–83.3) 97.9 (92.7–100.0) 77.1 (58.3–91.7) <0.001
Hypertension 1185 (79.7%) 1144 (73.1%) 995 (71.5%) 3324 (74.8%) <0.001
History of type 2 diabetes mellitus 683 (45.9%) 618 (39.5%) 567 (40.7%) 1868 (42.0%) 0.004
History of atrial fibrillation 654 (44.0%) 575 (36.8%) 493 (35.4%) 1722 (38.8%) <0.001
Previous HF hospitalization 710 (47.8%) 739 (47.3%) 677 (48.6%) 2126 (47.9%) 0.642
Previous myocardial infarction 678 (45.6%) 694 (44.4%) 605 (43.5%) 1977 (44.5%) 0.249
Previous PCI 476 (32.0%) 547 (35.0%) 511 (36.7%) 1534 (34.5%) 0.008
Previous CABG 253 (17.0%) 281 (18.0%) 225 (16.2%) 759 (17.1%) 0.56
ACEI 818 (55.0%) 887 (56.7%) 781 (56.1%) 2486 (56.0%) 0.544
ARB 413 (27.8%) 428 (27.4%) 371 (26.7%) 1212 (27.3%) 0.501
ARNI 170 (11.4%) 168 (10.7%) 152 (10.9%) 490 (11.0%) 0.654
Diuretic 1430 (96.2%) 1470 (94.0%) 1260 (90.5%) 4160 (93.6%) <0.001
Digoxin 297 (20.0%) 287 (18.4%) 233 (16.7%) 817 (18.4%) 0.025
β-Blocker 1432 (96.3%) 1506 (96.3%) 1336 (96.0%) 4274 (96.2%) 0.653
(Continued )
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than death). The proportions of patients with missing 
KCCQ values were similar in the dapagliflozin and placebo 
groups at 4 months and 8 months (89.9% vs 89.6%; and 
88.7% vs 87.6%, respectively). The median KCCQ-TSS 
was 77.1 (interquartile range, 58.3–91.7). The number 
and proportion of patients in the KCCQ-TSS tertiles are 
shown in Table. Compared with participants with higher 
KCCQ-TSS scores at baseline, those with lower scores 
were younger, more often women, white, and enrolled in 
Europe and the Americas (and less likely to be enrolled in 
Asia—an observation also made in previous HFrEF global 
trials14). They also had a higher body mass index and na-
triuretic peptide levels; and a lower estimated glomerular 
filtration rate (Table); and were more likely to be in NYHA 
functional class III/IV than in class II, and to have type 2 
diabetes mellitus and atrial fibrillation. With respect to 
background HF medications, patients with lower baseline 
KCCQ-TSS were more frequently treated with mineralo-
corticoid receptor antagonists and diuretics. Baseline use 
of angiotensin receptor neprilysin inhibitor was generally 
low but similar across age groups. The proportion of pa-
tients treated with implantable cardiac devices was gen-
erally comparable across the KCCQ-TSS subgroups.
Clinical Outcomes
Patients with lower baseline KCCQ-TSS experienced high-
er rates of cardiovascular death or worsening HF (25.0%, 
17.3%, and 13.6% in patients across KCCQ-TSS tertiles 
of ≤65.6, 65.7–87.5, and >87.5, respectively; P<0.001). 
In the Cox proportional hazards models, patients with 
lower baseline KCCQ-TSS had a higher risk of cardiovas-
cular death or worsening HF (tertile >87.5: referent; tertile 
65.7–87.5: HR, 1.30 [95% CI, 1.08–1.56], P=0.006; tertile 
≤65.6: HR, 1.93 [95% CI, 1.62–2.30], P<0.001; Figure 1).
The effects of dapagliflozin on the range of clinical 
outcomes are summarized in Figure  2. Dapagliflozin 
reduced the primary outcome of cardiovascular death 
or worsening HF across the entire range of KKCQ-TSS, 
with no evidence of treatment effect heterogeneity; and 
with patients in each tertile experiencing a statistically 
significant benefit (HR [95% CIs] from lowest to highest 
tertile: HR, 0.70 [95% CI, 0.57–0.86]; HR, 0.77 [95% 
CI, 0.61–0.98]; and HR, 0.62 [95% CI, 0.46–0.83], re-
spectively; P for heterogeneity = 0.52). Similar results 
were observed for cardiovascular death or hospitaliza-
tion for HF; worsening HF events; HF hospitalizations; 
cardiovascular death; and all-cause death (Figure 2; all 
P values for heterogeneity nonsignificant).
Health Status Outcomes
The mean changes in KCCQ-TSS, CSS, and OSS over 
time are presented in Figure 3A through 3C, respective-
ly. Patients treated with dapagliflozin had a modest but 
significant improvement in mean KCCQ-TSS, CSS, and 
OSS at 4 months (1.9, 1.8, and 1.7 points higher than 
placebo, respectively; P<0.0001 for all). These differenc-
es between dapagliflozin and placebo were amplified 
over time, with the corresponding mean differences at 8 
months being 2.8, 2.5, and 2.3 points higher in favor of 
dapagliflozin versus placebo (P<0.0001 for all).
The results of the responder analysis are shown in 
Figure 4A through 4D. Fewer patients treated with 
dapagliflozin had a clinically significant deteriora-
tion (≥5 point decline in KCCQ-TSS [25.3% versus 
32.9%; OR, 0.84 {95% CI, 0.78–0.90}, P<0.0001]); 
and more patients treated with dapagliflozin had 
at least small (58.3% versus 50.9%), moderate 
(54.5% versus 47.6%), and large (54.0% versus 
Mineralocorticoid receptor 
antagonists
1098 (73.8%) 1118 (71.5%) 933 (67.0%) 3149 (70.9%) <0.001
Antiplatelet 774 (52.1%) 862 (55.1%) 781 (56.1%) 2417 (54.4%) 0.028
Anticoagulant 674 (45.3%) 642 (41.0%) 567 (40.7%) 1883 (42.4%) 0.012
Statin 985 (66.2%) 1054 (67.4%) 944 (67.8%) 2983 (67.1%) 0.366
History of ICD 302 (20.3%) 336 (21.5%) 283 (20.3%) 921 (20.7%) 0.975
CRT-D 94 (6.3%) 96 (6.1%) 90 (6.5%) 280 (6.3%) 0.879
Cardiac pacemaker (CRT-D or 
CRT-P)
117 (7.9%) 119 (7.6%) 107 (7.7%) 343 (7.7%) 0.852
History of ICD or CRT-D 396 (26.6%) 432 (27.6%) 373 (26.8%) 1201 (27.0%) 0.910
Data are mean (SD), medians (interquartile range), or number (%). ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin 
II receptor blockers; ARNI, angiotensin receptor neprilysin inhibitor; BP, blood pressure; CABG, coronary artery bypass grafting; CRT-D, cardiac 
resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; eGFR, estimated glomerular filtration rate; HF, heart 
failure; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and TSS, total 
symptom score.
Table. Continued
KCCQ-TSS at Baseline
P Value for 
TrendTertile 1 N=1487 Tertile 2 N=1564 Tertile 3 N=1392 Total N=4443
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48.2%) improvements (corresponding OR [95% CI]: 
OR, 1.15 [95% CI, 1.08–1.23]; OR, 1.15 [95% CI, 
1.08–1.22]; OR, 1.14 [95% CI, 1.07–1.22]; NNT 
[95% CI]: NNT, 14 [95% CI, 10–23]; NNT, 15 [95% 
CI, 11–25]; and NNT, 18 [95% CI, 12–35], respec-
tively; P<0.0001 for all; Figure 4A and 4B). The find-
ings were similar for KCCQ-CSS and OSS (Figure 4C 
through 4F).
DISCUSSION
In this prospective study, which evaluated prespecified as-
sessments of health status using KCCQ in the DAPA-HF tri-
al, we observed that treatment with dapagliflozin reduced 
the risk of all key clinical events, including the primary 
composite end point of cardiovascular death or worsen-
ing HF, and its components, to a similar extent across the 
Figure 1. Time to first event of cardiovascu-
lar death or worsening heart failure accord-
ing to KCCQ-TSS tertile at randomization. 
Tertile >87.5: referent; tertile 65.7–87.5: HR, 
1.30 (95% CI, 1.08–1.56), P=0.006; tertile 
≤65.6: HR, 1.93 (95% CI, 1.62–2.30), P<0.001. 
HR indicates hazard ratio; KCCQ, Kansas City 
Cardiomyopathy Questionnaire; and TSS, total 
symptom score.
Figure 2. Effects of dapagliflozin as compared with placebo on the clinical events across the tertiles of KCCQ-TSS at baseline. 
HR indicates hazard ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; and TSS, total symptom score.
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entire range of KCCQ at baseline, indicating that the ben-
eficial effects of dapagliflozin on HF outcomes are inde-
pendent of the health status impairment at baseline. Fur-
thermore, dapagliflozin significantly improved KCCQ-TSS, 
CSS, and OSS (which collectively encompass symptoms, 
physical function, quality of life, and social function), and 
these effects were amplified over time. Finally, significant-
ly fewer patients treated with dapagliflozin experienced 
clinically meaningful deterioration, and significantly more 
experienced at least small, moderate, and large clinically 
meaningful improvements in health status. These effects 
were substantial, with NNT ranging between 12 and 18 
after just 8 months of treatment.
Our results have several important implications. First, 
our analyses of the clinical outcomes across the subgroups 
of baseline KCCQ-TSS show no evidence of heterogene-
ity in the benefit of dapagliflozin by the magnitude of 
symptomatic impairment at baseline. Previously reported 
prespecified subgroup analyses of the primary end point 
(cardiovascular death or worsening HF) suggested that 
the benefit of dapagliflozin may be more pronounced in 
patients with NYHA class II versus class III to IV. 6 How-
ever, NYHA class, although prognostically important, 
represents a more subjective, arbitrary, and non–patient-
centric assessment of symptom burden; and considering 
this report, the observation from the previous NYHA class 
subgroup analysis was likely a chance finding.
Second, our findings substantially expand on the pre-
viously reported effects of dapagliflozin on health sta-
tus, as measured by KCCQ, in patients with HFrEF. In 
the DEFINE-HF trial (Dapagliflozin Effects on Biomarkers, 
Symptoms, and Functional Status in Patients With Heart 
Failure With Reduced Ejection Fraction), a modestly sized 
randomized, placebo-controlled trial performed across 
26 sites in the United States, dapagliflozin was also 
shown to have favorable effects on several domains of 
KCCQ—with slightly greater mean differences in favor 
of dapagliflozin versus placebo (ie, 4.8 points for KC-
CQ-TSS) than those observed in the DAPA-HF trial, but 
comparable responder analyses and NNT (ie, NNT of 10 
for 5-point or greater improvement in KCCQ-OSS), after 
just 12 weeks of treatment.15 Our findings confirm these 
beneficial effects on symptoms, function, and quality 
of life in a much larger, global trial, with a longer dura-
tion of follow-up and the ability to assess the effects of 
dapagliflozin on clinical outcomes across the range of 
baseline KCCQ. Collectively, these complimentary find-
ings from both the DEFINE-HF and DAPA-HF trials indi-
cate that dapagliflozin significantly improves HF-related 
health status, as measured by KCCQ, with the benefits 
emerging early and being sustained long-term.
Third, the magnitude of the improvement in KCCQ 
that we observed with dapagliflozin versus placebo in 
the DAPA-HF trial compares favorably with other effica-
cious therapies for HFrEF. As an example, in the SHIFT 
trial (Systolic Heart Failure Treatment With the If Inhibitor 
Ivabradine Trial),16 ivabradine demonstrated a 2.4-point 
mean improvement in KCCQ-OSS, and a 1.8-point mean 
improvement in KCCQ-CSS after 12 months of treat-
ment. In the PARADIGM-HF study (Prospective Compari-
son of ARNI [Angiotensin Receptor Neprilysin Inhibitor] 
With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to 
Determine Impact on Global Mortality and Morbidity in 
Heart Failure),17 sacubitril-valsartan demonstrated 1.3- 
and 0.9-point improvements in KCCQ-OSS and KCCQ-
CSS, respectively, over enalapril after 8 months of treat-
ment (although true baseline measurement of KCCQ 
was not done, which complicates the interpretation of 
these data). In the HF-ACTION trial (Heart Failure: A Con-
trolled Trial Investigating Outcomes of Exercise Training), 
exercise therapy in HFrEF produced a 1.9-point improve-
ment in KCCQ-OSS.18 In the MADIT-CRT study (Multi-
center Automatic Defibrillator Implantation Trial With 
Cardiac Resynchronization Therapy)19 in patients with 
HFrEF and prolonged QRS interval, treatment with car-
diac resynchronization therapy resulted in 2.0-, 2.0-, and 
Figure 3. Effects of dapagliflozin compared with placebo on KCCQ 
scores over 8 months.  
Effects of dapagliflozin as compared with placebo on mean (A) KCCQ-TSS, (B) 
KCCQ-CSS, and (C) KCCQ-OSS over 8 months of treatment. Analysis includes 
those patients that are alive at the time of the KCCQ assessment (ie, 4 months 
and 8 months). CSS indicates clinical summary score; KCCQ, Kansas City 
Cardiomyopathy Questionnaire; OSS, overall summary score; and TSS, total 
symptom score.
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2.4-point improvements in KCCQ-TSS, CSS, and OSS, re-
spectively, in patients with left bundle branch block, and 
no significant improvements in KCCQ among patients 
without left bundle branch block. It should be noted, 
however, that comparisons of mean between-group 
differences in KCCQ do not adequately reflect clinically 
important changes in individual patients (because the ef-
fects are averaged across large populations). Therefore, 
from a clinical standpoint, the responder analyses that 
calculate the proportions of individual patients who ex-
perience a clinically meaningful change (deterioration or 
improvement in KCCQ) are more informative. Although 
few responder analyses had been done previously, the 
magnitude of benefit (including NNT) observed with 
dapagliflozin in the responder analyses of DAPA-HF 
also compare very favorably with previously observed 
results.16,17 It should further be noted that the NNT for 
clinically meaningful improvements in KCCQ observed in 
the DAPA-HF trial should be interpreted in the context of 
comparing dapagliflozin-treated patients with those that 
received placebo (who also experienced an improvement 
in health status, consistent with a sizable “placebo ef-
fect,” seen in our study, in the DEFINE-HF trial with dapa-
gliflozin, and in placebo-controlled trials of other agents 
in HFrEF).16 Given the importance of reducing symptom 
burden and functional limitations and improving the 
quality of life—a key goal of HF management endorsed 
by the practice guidelines and regulators—our findings 
provide further support for dapagliflozin as a new treat-
ment option for patients with HFrEF. 
The results of our study should be considered in the 
context of several potential limitations. Although KCCQ 
was a predefined secondary end point, and prospective 
assessments of health status were specified in protocol, 
the evaluation of clinical outcomes (such as cardiovascular 
death or worsening HF) by tertiles of baseline KCCQ-TSS 
Figure 4. Responder analyses of clinically meaningful change in KCCQ at 8 months with dapagliflozin versus placebo.  
Responder analyses of clinically meaningful changes in (A and B) KCCQ-TSS, (C and D) KCCQ-CSS, and (E and F) KCCQ-OSS with dapagliflozin vs placebo at 8 
months. Deaths are treated as not improved or as deteriorated (for the improvement and deterioration calculations, respectively). CSS indicates clinical summary 
score; Dapa, dapagliflozin; KCCQ, Kansas City Cardiomyopathy Questionnaire; NNT, number needed to treat (numbers in parentheses represent 95% CIs); OR, 
odds ratio; OSS, overall summary score; and TSS, total symptom score.
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was done post hoc. The number of black patients was 
relatively small, although similar to other global HFrEF 
trials. KCCQ data were missing in a small proportion of 
patients. As in other trials, the prespecified inclusion and 
exclusion criteria will have reduced enrollment of hospi-
talized and other very high-risk patients. These limitations 
may affect the generalizability of our results.
Conclusions
In the DAPA-HF trial, treatment with dapagliflozin re-
duced death and HF hospitalizations across the range 
of baseline KCCQ values, and improved symptom bur-
den, functional status, and quality of life in patients 
with HFrEF. Furthermore, dapagliflozin significantly in-
creased the proportion of patients experiencing small, 
moderate, and large improvements in health status; 
these effects were clinically important.
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